* IDEC Pharmaceutical Corp., of San Diego, and Genentech Inc., ofSouth San Francisco, expanded their collaboration to include clinicaldevelopment and commercialization of IDEC-Y2B8, IDEC'sradioconjugate expected to go into Phase II studies this year in B celllymphomas. IDEC will receive a $1.5 million option fee and up to$1.5 million toward the upcoming trial. Further details are beingnegotiated.

* Cephalon Inc., of West Chester, Pa., will co-promote Serzone, anantidepressant manufactured by Bristol-Myers Squibb Co., in theU.S. The companies also are extending for one year their three-yearagreement under which Cephalon is co-promoting Stadol NasalSpray, a synthetic opioid analgesic.

* Rhone-Poulenc Rorer Inc., of Collegeville, Pa., said Taxotere isnow available in France for the treatment of advanced breast cancer.

* Somatogen Inc., of Boulder, Colo., submitted an investigationalnew drug application to begin clinical studies of its recombinanthuman hemoglobin, rHb1.1, as an agent for stimulating red blood cellformation. The company hopes to start a randomized, double-blind,dose-ranging study in about 75 anemic patients with end-stage renaldisease who have been on hemodialysis for six months or more, andwho are responding to erythropoietin.

* Procept Inc., of Cambridge, Mass., presented preclinical datashowing a series of small molecule compounds, known as PIC 060analogues, demonstrated in vitro activity and in vivo suppression ofallograft transplant rejection. The compounds inhibit CD4+ cellproliferation, and could be useful in organ transplant rejection andautoimmune diseases.

(c) 1997 American Health Consultants. All rights reserved.